Hide menu

New setback for diabetes vaccine

Vaccination with the antigen GAD does not, in isolation, appear to be able to restrict the progression of type-1 diabetes. Another study, conducted in North America and published in the journal Lancet, also indicates negative results.

Just prior to midsummer, the Swedish pharmaceutical company Diamyd announced the suspension of the U.S. phase-3 study that was going to present their results during 2012.

The study being presented at the American Diabetes Association Congress 2011 in San Diego and in the Lancet Online First was performed on 145 patients who fell ill within 100 days. The research team, led by Dr. Jay S Skyler at the Diabetes Research Institute in Miami, USA, reports that the production of insulin was not preserved better in patients who received active vaccine than for those injected with an ineffective placebo.

The authors still believe that the GAD vaccine could produce beneficial effects if administered even earlier, or in combination with other treatments. In a commentary in the Lancet, two Belgian experts, Dr. Chantal Mathieu and Dr Pieter Gillard, are hopeful that GAD may still play a role via a combination of treatments for type-1 diabetes.

During May 2011, the European Phase 3 study, led by Professor Johnny Ludvigsson at Linköping University, was presented which also yielded negative results.

The article Antigen-based therapy with Glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomized double-blind trial of Diane K Wherrett et al is published in the Lancet Online First 27 June 2011. Abstract

Åke Hjelm Tue Jun 28 09:37:00 CEST 2011

LiU magazine

Page manager: anna.nilsen@liu.se
Last updated: Tue Jun 07 07:54:13 CEST 2016